Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urinary detection of recombinant luteinising hormone in healthy men
ACTRN12609000300279Phase 4Not yet recruiting
- Sponsor
- Sydney South West Area Health Authority
- Start
- May 2009
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lutropin alfa and nandrolone (2 arms), sponsored by Sydney South West Area Health Authority. Primary endpoint: Rise in urinary recombinant luteinising hormone detected by immunoassay. Planned start May 2009; status: not yet recruiting.
02
Drugs
lutropin alfanandrolone
Beyond the preview
Go deeper on ACTRN12609000300279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000300279.